Combination loxapine and aripiprazole for refractory hallucinations in schizophrenia

Annals of Pharmacotherapy

Volumn 45, Issue 7-8, 2011, Pages

  Sokolski, Kenneth N ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Aripiprazole; Hallucinations; Loxapine; Refractory symptoms; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; HALOPERIDOL DECANOATE; LAMOTRIGINE; LOXAPINE; OLANZAPINE; PROPRANOLOL; RISPERIDONE; TIOTIXENE; ZIPRASIDONE;

ADULT; ARTICLE; AUDITORY HALLUCINATION; BEDTIME DOSAGE; CASE REPORT; COMBINATION CHEMOTHERAPY; DISORIENTATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERSALIVATION; MALE; MONOTHERAPY; MUSCLE CRAMP; PARANOID SCHIZOPHRENIA; PERSECUTORY DELUSION; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT REFUSAL; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TREMOR;

EID: 79960777400     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q088     Document Type: Article

References (25)

1. Van Sant SP and Buckley PF. Pharmacotherapy for treatment-refractory schizophrenia. Expert Opin Pharmacother 2011;12:411-434.
2. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992;17(suppl):41-45.
3. Lerner V. High-dose olanzapine for treatment-refractory schizophrenia. Clin Neuropharmacol 2003;26:58-61.
4. Pierre JM, Wirshing DA, Wirshing WC, et al. High-dose quetiapine in treatment refractory schizophrenia. Schizophr Res 2005;73:373-375.
5. Melnik T, Soares BG, Puga ME, Atallah AN. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole, and paliperidone) compare with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. Sao Paulo Med J 2010;128:141-166.
6. Becher NM, Kaup BA. Combining risperidone with standard neurolep-tics for refractory schizophrenic patients. Am J Psychiatry 1996;153:137.
7. Aziz MA, Pepler A, Mcneely C, Gorman JM. Remission of positive and negative symptoms in refractory schizophrenia with a combination of haloperidol and quetiapine: two case studies. J Psychiatr Pract 2006;12: 332-336.
8. Honer WG, Thronton AE, Chen E Y, et al. Clozapine alone versus cloza-pine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354:472-482.
9. Cobo-Gomez J V, Fuste G, Coronas R, et al Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients. Curr Drug Saf 2008;3:210-215.
10. Collins EJ, Hogan TP, Awad AG. The pharmacoepidemiology of treatment-refractory schizophrenia. Can J Psychiatry 1992;37:192-195.
11. Kessler RM, Woodward ND, Riccardi P, et al. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 2009;65:1024-1031.
12. Perez-Costas E, Melendez-Ferro M, Roberts RC. Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem 2010;113:287-302.
13. Ballenger B, Strafella AP, van Emeren T, et al. Serotonin 5HT2A receptors and visual hallucinations in Parkinson's disease. Arch Neurol 2010;67:416-421.
14. Kang K, Huang XF, Wang Q, Deng C. Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia-a postmortem study. Prog Neuropsychopharmacol Biol Psychiatry 2009;33: 867-871.
15. Kuo J, Hwu HG. Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient. Clin Neuropharmacol 2008;31: 173-175.
16. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in cloza-pine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled tiral. J Clin Psychiatry 2008;69: 720-731.
17. Hsu WY, Lee CI, Chiu NY, Kahn DA. Aripiprazole in treatment-refractory schizophrenia. J Psychiatr Pract 2009;15:221-226.
18. Mossaheb N, Spindelegger C, Asenbaum S, Fisher P, Barnas C. Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine. World J Biol Psychiatry 2010;11:502-505.
19. Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S. PET evidence that loxapine is an equipotent blocker of 5HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997;154:1525-1529.
20. Glazer WM. Does loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry 1999;60(suppl 10):42-48.
21. Lehman CR, Ereshesfsky L, Saklad SR, Mings TE. Very high dose loxapine in refractory schizophrenic patients. Am J Psychiatry 1981;138: 1212-1214.
22. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8:193-197.
23. Sing AN, Barlas C, Sing S, Franks P, Mishra RK. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4, and serotonin 5HT2 receptor subtypes. J Psychiatry Neurosci 1996;21:29-35.
24. Kapur S, Zipursky RB, Jones C, et al. The D2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 1996;15:562-566.
25. Meltzer H Y, Jayathilake K. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine? J Clin Psychiatry 1999;60(suppl 10):47-51.